ATE483973T1 - Cross-spot - Google Patents
Cross-spotInfo
- Publication number
- ATE483973T1 ATE483973T1 AT07834636T AT07834636T ATE483973T1 AT E483973 T1 ATE483973 T1 AT E483973T1 AT 07834636 T AT07834636 T AT 07834636T AT 07834636 T AT07834636 T AT 07834636T AT E483973 T1 ATE483973 T1 AT E483973T1
- Authority
- AT
- Austria
- Prior art keywords
- immune effector
- antigen
- cross spot
- spot
- cross
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85176506P | 2006-10-16 | 2006-10-16 | |
| EP06122334 | 2006-10-16 | ||
| PCT/NL2007/050498 WO2008048097A1 (en) | 2006-10-16 | 2007-10-16 | Cross-spot |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE483973T1 true ATE483973T1 (de) | 2010-10-15 |
Family
ID=37495887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07834636T ATE483973T1 (de) | 2006-10-16 | 2007-10-16 | Cross-spot |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110059430A1 (de) |
| EP (1) | EP2080024B1 (de) |
| AT (1) | ATE483973T1 (de) |
| DE (1) | DE602007009713D1 (de) |
| WO (1) | WO2008048097A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3421997T1 (sl) | 2012-12-28 | 2020-10-30 | Cellestis Limited | Test celično posredovanega imunskega odziva |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ214400A (en) * | 1985-12-02 | 1989-05-29 | Univ Otago | Detecting infection in ruminant including conducting assay of mononuclear cell function |
| US6284255B1 (en) * | 1996-08-29 | 2001-09-04 | Genesis Research & Development Corporation Limited | Compounds and methods for treatment and diagnosis of mycobacterial infections |
-
2007
- 2007-10-16 DE DE602007009713T patent/DE602007009713D1/de active Active
- 2007-10-16 US US12/445,702 patent/US20110059430A1/en not_active Abandoned
- 2007-10-16 AT AT07834636T patent/ATE483973T1/de not_active IP Right Cessation
- 2007-10-16 WO PCT/NL2007/050498 patent/WO2008048097A1/en not_active Ceased
- 2007-10-16 EP EP07834636A patent/EP2080024B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2080024A1 (de) | 2009-07-22 |
| DE602007009713D1 (en) | 2010-11-18 |
| WO2008048097A1 (en) | 2008-04-24 |
| US20110059430A1 (en) | 2011-03-10 |
| EP2080024B1 (de) | 2010-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
| CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| BR122018069446B8 (pt) | método in vitro para detectar a presença de um célula de câncer em um indivíduo | |
| EP2321430B8 (de) | Verfahren zur bewertung des oralkarzinomrisikos bei menschen | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| MX2011006422A (es) | Autoanticuerpos humanos anti-alfa-sinucleina. | |
| CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
| EA201101520A1 (ru) | Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| CY1115932T1 (el) | Σκευασμα αντισωματος | |
| MX2009005189A (es) | Anticuerpos humanos monoclonales para btla y metodos de uso. | |
| AU2011343161A8 (en) | Human anti-SOD1 antibodies | |
| MX345092B (es) | Anticuerpos anti-tau humanos,. | |
| EP4434550A3 (de) | Menschliche antikörper-arzneimittelkonjugate gegen den gewebefaktor | |
| NO20083062L (no) | Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1 | |
| NO20081124L (no) | Anti-CD 3 antistoff-formuleringer | |
| ATE489465T1 (de) | Gezielte integration in die ppp1r12c-position | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
| ATE556717T1 (de) | Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus | |
| CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
| WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
| ATE483973T1 (de) | Cross-spot | |
| GB0706558D0 (en) | Diagnostic assay | |
| BRPI0606619A2 (pt) | método de análise de oligossacarìdeos, a partir do plasma sangüìneo | |
| MX2012005595A (es) | Proteina marcadora para diabetes de tipo 2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |